He has received almost continuous funding from NIH for 39 years. He has served on many NIH study sections, including serving as permanent member of Drug Discovery and Mechanisms of Antimicrobial Resistance and Microbial Physiology, on the editorial board of Antimicrobial Agents and Chemotherapy (21 years), and as Associate Editor of the journal Microbiology. Dr. Becker has served as a consultant to the pharmaceutical companies Eli Lilly, Merck, Smith-Kline Beckman, Magainin Sciences, and Elitra. Dr. Becker was one of the four founders and member of the scientific advisory board of a new biotechnology company located in Cambridge, Massachusetts, whose goal was to find and develop new drugs for infectious diseases. That company, Mycopharmaceuticals, Inc., merged subsequently with Millenium Pharmaceuticals, Inc. The research carried out in Dr. Becker’s laboratory involves the molecular biology of membrane transport, the structure and function of peptide pheromones/hormones and their receptors, and the discovery of fungal virulence factors. Dr. Becker trained over thirty-five doctoral and masters students who took post-doctoral fellowships at institutions including U. California-Berkeley, Columbia University, Johns Hopkins, Case Western, Vanderbilt, Harvard, and CalTech. His former students now hold faculty or staff positions at St. Michael’s College, U. Alabama, National Cancer Institute, FDA, New Mexico State, Nebraska Wesleyan, Centers for Disease Control-Atlanta, Clark Atlanta U., Rhodes College, Mercer U., U. North Dakota, Purdue, and Case Western. His laboratory hosted over two hundred undergraduate research fellows.